The National Institute on Drug Abuse (NIDA) awarded a $701,959 project grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Regents of the University of Michigan to improve perioperative care for patients with opioid tolerance. The 5-year project aims to: Capture patient-reported opioid use and pain outcomes among opioid-tolerant individuals undergoing common surgical procedures to calibrate current prescribing guidelines. Develop a clinical care pathway for...
This $832,886 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) seeks to evaluate a novel, non-pharmacological pain relief device called the Neurocuple for managing postoperative pain in patients undergoing total knee arthroplasty (TKA) surgery. The funded research involves a randomized, placebo-controlled clinical trial with 120 TKA patients to assess the effectiveness of the Neurocuple device in reducing opioid...
This $1,500,000 federal Project Grant award from the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance program (CFDA 93.243) will enable the Icahn School of Medicine at Mount Sinai to adapt and implement opioid-sparing pain management protocols across the Mount Sinai Health System's eight emergency departments in New York City. The project aims to create a systematic approach to...
The University of Miami is conducting a research project under a $1,109,446 Cooperative Agreement awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH). The project, funded through the Drug Abuse and Addiction Research Programs (CFDA 93.279), aims to develop a novel non-opioid analgesic based on gene therapy targeting the carbonic anhydrase-8 (CA8) protein to treat chronic pain associated with knee osteoarthritis. The...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to investigate a novel, non-opioid spinal analgesic mechanism for treating high impact chronic pain conditions. The $664,772 award to The University of Texas Southwestern Medical Center aims to evaluate the signaling pathways involved in the activation of the...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $327,864 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Opsin Biotherapeutics Inc. to develop an optogenetic pain modulator for non-opioid chronic pain management. The project aims to optimize the optical delivery and wireless stimulation device for the Multi-Characteristic Opsin (MCO) that can be delivered to pain-sensing neurons and stimulated to minimize pain perception. The...
This $295,906 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to integrate an opioid medication management system called the ADDINEX platform into a hospital pharmacy's workflows. The goal is to reduce opioid use by emergency department patients upon discharge. Key aspects include: Adapting the ADDINEX system, which uses secure dispensers and mobile app passcodes to control opioid access, to work...
The Substance Abuse and Mental Health Services Administration (SAMHSA) awarded a $1,397,454 Project Grant under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program to Kettering Medical Center Network in Kettering, Ohio. The 3-year grant, effective September 30, 2024, will fund the implementation of the PAUSE Pathway for Opioid Alternatives in the Emergency Department. The project aims to: 1) Revitalize and update the PAUSE...
This $238,500 Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will fund a randomized, blinded clinical trial to quantify the opioid-sparing properties of a telemedicine-delivered digital cognitive behavioral intervention (DCBI) for patients undergoing total knee and hip arthroplasty (THA/TKA) surgeries. The central hypothesis is that preoperative DCBI will decrease perioperative anxiety, depression,...
This $13,718,085 Cooperative Agreement, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the clinical development of PF614-MPAR, an opioid analgesic with built-in abuse-deterrent and overdose protection features. The key product being developed is PF614-MPAR, a combination product comprising the TAAP-oxycodone prodrug PF614 and the trypsin inhibitor nafamostat. This novel formulation is designed to provide pain...